Not quite comparable since death from any cause may have included patients who were not mechanically ventilated. Which actually makes it worse for tocilizumab since leronlimab had a tougher patient population.

Quote:

---

The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group

---

Quote:

---

Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, –5.2 to 7..

---